Photo by nci from unsplash
vation of CD56+ NKC as opposed to NR (Figure 1). NKC cytotoxicity through the expression of Granzyme B was seen in R vs NR. Flow quantitation of circulating CD4+ CD25+… Click to show full abstract
vation of CD56+ NKC as opposed to NR (Figure 1). NKC cytotoxicity through the expression of Granzyme B was seen in R vs NR. Flow quantitation of circulating CD4+ CD25+ T cells (Tregs) shows a decrease in R vs. NR. Conclusions: AFM13 demonstrated a high ORR of 44 % among a population of heavily pretreated patients with a CD30 positive lymphoproliferative T-cell malignancy. AFM 13 exhibited activity post brentuximab vedotin failure. In addition, biological changes in NKC infiltration and activation in the PB and tissue biopsy correlate with response. This data is the first to demonstrate the therapeutic advantages of this bispecific, and the first to correlate changes in NKC as a function of dose and schedule.
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!